Lantern Pharma Expands AI Platform to Broader Therapeutic Development — Lantern Pharma Inc.

Event summary

Lantern Pharma to host webinar on September 23, 2026, detailing Open-Medicine AI's business model, roadmap, and value proposition.
Open-Medicine AI extends AI co-scientist approach beyond rare cancers to new disease categories and therapeutic modalities.
Platform aims to address downstream development challenges, including trial design, patient selection, and regulatory strategy.
AI in drug discovery market estimated at $2.9 billion in 2026, projected to grow to $13.8 billion by 2033.
Open-Medicine AI to generate revenue through subscription access and enterprise licensing.

The big picture

Lantern Pharma's expansion of its AI platform into broader therapeutic development aligns with the industry's shift towards enterprise-scale, agentic AI systems. The company's approach, built within active clinical programs, positions it uniquely to address the time, cost, and failure challenges inherent in drug development. The growing AI in drug discovery market and the increasing adoption of AI deployments in pharma underscore the strategic significance of this move.

What we're watching

Market Adoption: How Open-Medicine AI will be adopted by industry professionals and service providers.
Execution Risk: Whether Lantern Pharma can successfully extend the platform beyond rare cancers and into new disease categories.
Revenue Growth: The pace at which Open-Medicine AI can generate significant revenue through subscription and enterprise licensing.